newsfilter
← Latest News
GlobeNewswire·

ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights

-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan; European CHMP opinion expected this month -- -- Pipelin